Sona Nanotech Inc SNANF

Primary Symbol: C.SONA

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.

CSE:SONA - Post by User

Sona Nanotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Mar 25, 2024 3:48pm

182 Views

Post# 35951433

Sona Nanotech Updates on Dalhousie Efficacy Study

Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results (newsfilecorp.com)

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing